---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-055919"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:02:31.809723+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics amends Series B Preferred terms to allow board discretion to convert to common stock

## Summary
- On Feb 12, 2026, Galera filed a Certificate of Amendment to its Series B Preferred Certificate of Designation.
- Amendment grants the board sole discretion to convert Series B Preferred into common stock using the Conversion Ratio.
- Amendment was approved by the board and by unanimous written consent of Series B holders.
- No immediate conversion; board may elect to convert in whole or in part at a later date.

## SEC filing metadata
- accession: 0001193125-26-055919
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312526055919/0001193125-26-055919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312526055919/d60666d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-055919
- JSON: https://secwatch.observer/filing/0001193125-26-055919.json
- Plain text: https://secwatch.observer/filing/0001193125-26-055919.txt

## Source-grounded claims
- claim_id: 8302ab71a54e2d066b74caa6096da5da73186ff6
  claim: Galera Therapeutics, Inc.: Amended Series B Preferred Stock Certificate of Designation to allow board discretion to convert shares to Common Stock based on Conversion Ratio (effective 2026-02-12).
  evidence_excerpt: On February 12, 2026, Galera Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312526055919/0001193125-26-055919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.